Antares Pharma, Inc. Announces Filing of New Drug Application for Anturol for Overactive Bladder

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Anturol® Gel in patients with overactive bladder (OAB).